From Discovery To Development To Delivery
AZBio is committed to building a top-tier life science industry in Arizona.
AZBio Members Are Making LIFE Bettter
AZBio Members discover, develop, and deliver life-saving and life-changing innovations.
Get Connected With Arizona's Bioindustry
A key component in Arizona’s life science ecosystem, the Arizona Bioindustry Association (AZBio) is the only statewide organization exclusively focused on Arizona’s bioscience industry. AZBio membership includes patient advocacy organizations, life science innovators, educators, healthcare partners and leading business organizations. AZBio is the statewide affiliate of the Biotechnology Innovation Organization (BIO) and works in partnership with AdvaMed, MDMA, and PhRMA to advance innovation and to ensure that the value delivered from life-changing and life-saving innovation benefits people in Arizona and around the world.
Success Stories – Good News from Arizona’s BioIndustry
Latest Deal Builds on Success of MDUFA III
Avery Therapeutics, Inc., a pre-clinical stage company dedicated to advancing tissue-engineered therapeutics to treat diseases and injuries to human muscle, has been awarded a $483k SBIR grant from the National Institutes of Health to develop manufacturing, cryopreservation, storage and reconstitution methods for Avery’s first product MyCardia™.
Marni Landry of the Paradise Valley High School CREST Program Named Arizona Bioscience Educator of the Year
The Arizona Bioindustry Association has named Marni Landry, BS, M.Ed of Paradise Valley High School as the 2016 Michael A. Cusanovich Bioscience Educator of the Year in recognition of her dedication in the classroom and her commitment to designing bioscience education programs and curriculum to help inspire and create tomorrow’s bioscience leaders.
Insys Therapeutics Announces First Patient Enrolled in Phase II Trial for the Treatment of Cocaine Dependence Using Pharmaceutical Cannabidiol
Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “the Company”) today announced enrollment of the first patient in a Phase II clinical trial for the treatment of cocaine dependence using its pharmaceutical cannabidiol (CBD) product candidate. The study is being conducted by Dr. Didier Jutras-Aswad, MD, at the University of Montreal Hospital Research Center (CRCHUM) and is […]
- BioPharm America 2016
- 09/13/2016 - 09/15/2016
- RESI Boston 2016
- Medical Device Product Development for Startups - The Bitter Pill
- SBIR: Ask The Experts - Getting your first award
- SBIR: Ask The Experts - Moving Forward